Arcellx, Inc.
ACLX
Classificação em ações
#2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Preço da ação
$115.07
Última sincronização: 2026-05-15
Valor de mercado
$6.73B
Variação (1 dia)
0.00%
Variação (1 ano)
32.61%
País
US
Negociar Arcellx, Inc. (ACLX)
Categoria
Healthcare
Rácio P/S de Arcellx, Inc. (ACLX)
Rácio P/S em October 2026 TTM: 475.55
De acordo com os relatórios financeiros mais recentes e o preço das ações da Arcellx, Inc., o rácio P/S atual (TTM) é 475.55. No final de 2023, o rácio P/S era 24.18.
Histórico do rácio P/S da Arcellx, Inc. de 2018 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 475.55 | 1,149.47% |
| 2024 | 38.06 | 57.41% |
| 2023 | 24.18 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | -97.89% |
US
|
|
| 40.55 | -91.47% |
US
|
|
| 3.96 | -99.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -97.87% |
NL
|
